HPRA Drug Safety Newsletter Edition 72

Download: hpra-drug-safety-newsletter-edition-72.pdf 360 KB

  The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

·   Bisphosphonates-small risk of osteonecrosis of the external auditory canal

·   Mycophenolate mofetil (CellCept) and Mycophenolic acid (Myfortic)-Risk of teratogenicity and new pregnancy prevention advise for women and men

·   The starting dose of thalidomide should be reduced when combined with melphalan in patients over 75 years of age

« Back